{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:58:47Z","timestamp":1794373127876,"version":"4.9.0"},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    In children, the clinical efficacy and immunological mechanisms of sublingual immunotherapy (SLIT) compared with subcutaneous immunotherapy (SCIT) is still to be elucidated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives<\/jats:bold>\n                    To compare SLIT, SCIT and pharmacotherapy in relation to clinical efficacy and immunological mechanisms that govern its effect in asthmatic\/rhinitis children who were sensitized to house dust mite (HDM).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    In this single centre, prospective, randomized, controlled, open labelled, three parallel group trial, 48 patients mono\u2010sensitized to HDM were randomized to receive either SLIT (\n                    <jats:italic>n<\/jats:italic>\n                    =16), SCIT (\n                    <jats:italic>n<\/jats:italic>\n                    =16) or pharmacotherapy alone (\n                    <jats:italic>n<\/jats:italic>\n                    =16). Symptom, medication and visual analogue score (VAS) were collected and bronchial\u2010nasal hyper\u2010reactivity, skin prick tests, total\u2010specific IgE were performed at baseline and 12 months after treatment. In addition, peripheral blood mononuclear cells were cultured with recombinant Der p 1 and Bet v 1 extracts and allergen\u2010specific IL\u20104, IL\u20105, IL\u201013, IFN\u2010\u03b3, IL\u201010, and TGF\u2010\u03b2 secretions were measured.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    SLIT and SCIT demonstrated a significant reduction of total rhinitis and asthma symptom score, total medication score, VAS and skin reactivity to HDM (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.05) when compared with pharmacotherapy. A significant reduction of serum\u2010specific HDM\u2010IgE in SCIT and SLIT were observed. Moreover, titrated nasal provocative dose significantly increased in both immunotherapy groups when compared with the pharmacotherapy group. No adverse effects were reported in SLIT, while two patients demonstrated serious adverse events in SCIT. After 1 year of treatment, Der p 1\u2010driven IL\u201010 significantly increased in SLIT compared with pharmacotherapy, whereas Bet v 1\u2010driven TGF\u2010\u03b2 (negative control) increased significantly in SLIT only. No changes were observed for Th1\u2013Th2 cytokines.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    Both SLIT and SCIT demonstrated clinical improvement compared with pharmacotherapy in asthma\/rhinitis children sensitized to HDM.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2222.2009.03448.x","type":"journal-article","created":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T21:26:13Z","timestamp":1264022773000},"page":"922-932","source":"Crossref","is-referenced-by-count":181,"title":["Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic\/rhinitis children sensitized to house dust mite: an open randomized controlled trial"],"prefix":"10.1111","volume":"40","author":[{"given":"A. O.","family":"Eifan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Akkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Keles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. N.","family":"Bahceciler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. B.","family":"Barlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69283-0"},{"key":"e_1_2_6_3_2","first-page":"247","article-title":"Prevalence of symptoms of asthma, rhinitis and eczema in 13\u2010 to 14\u2010year\u2010old children in Africa","volume":"62","author":"Ait\u2010Khaled N","year":"2007","journal-title":"the International Study of Asthma and Allergies in Childhood Phase III"},{"key":"e_1_2_6_4_2","first-page":"1","article-title":"WHO position paper. Allergen immunotherapy","volume":"53","author":"Bousquet J","year":"1998","journal-title":"therapeutic vaccines for allergic diseases"},{"key":"e_1_2_6_5_2","first-page":"5","article-title":"Diagnosis and treatment of asthma in childhood","volume":"63","author":"Bacharier LB","year":"2008","journal-title":"a PRACTALL consensus report"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.09.054"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2007.00549.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.1999.00267.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1934"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.06.013"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.03.001"},{"key":"e_1_2_6_12_2","volume-title":"NHLBI\/WHO Workshop report. GINA Guidelines","author":"Global Initiative for Asthma Management and Prevention.","year":"2006"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01219_1.x"},{"key":"e_1_2_6_14_2","first-page":"45","article-title":"Clinical efficacy of sublingual and subcutaneous birch pollen allergen\u2010specific immunotherapy","volume":"59","author":"Khinchi MS","year":"2004","journal-title":"a randomized, placebo-controlled, double-blind, double-dummy study"},{"key":"e_1_2_6_15_2","first-page":"1253","article-title":"Sublingual versus injective immunotherapy in grass pollen allergic patients","volume":"26","author":"Quirino T","year":"1996","journal-title":"a double blind (double dummy) study"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62726-3"},{"key":"e_1_2_6_17_2","first-page":"119","article-title":"Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis","volume":"39","author":"Mauro M","year":"2007","journal-title":"a randomized study"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000124286"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2007.00604.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001186"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001936.pub2"},{"key":"e_1_2_6_22_2","first-page":"4","article-title":"Sublingual immunotherapy for allergic rhinitis","volume":"60","author":"Wilson DR","year":"2005","journal-title":"systematic review and meta-analysis"},{"key":"e_1_2_6_23_2","first-page":"9","article-title":"Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta\u2010analysis","volume":"15","author":"Olaguibel JM","year":"2005","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_6_24_2","first-page":"141","article-title":"Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age","volume":"97","author":"Penagos M","year":"2006","journal-title":"a meta-analysis of randomized, placebo-controlled, double-blind trials"},{"key":"e_1_2_6_25_2","first-page":"87","article-title":"Grass pollen immunotherapy for seasonal rhinitis and asthma","volume":"107","author":"Walker SM","year":"2001","journal-title":"a randomized, controlled trial"},{"key":"e_1_2_6_26_2","first-page":"1120","article-title":"Grass pollen immunotherapy","volume":"121","author":"Francis JN","year":"2008","journal-title":"IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.02.012"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083956"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02429.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087358"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.4049\/jimmunol.154.8.4187","article-title":"Bee venom immunotherapy results in decrease of IL\u20104 and IL\u20105 and increase of IFN\u2010gamma secretion in specific allergen\u2010stimulated T cell cultures","volume":"154","author":"Jutel M","year":"1995","journal-title":"J Immunol"},{"key":"e_1_2_6_32_2","first-page":"56","article-title":"Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1","volume":"105","author":"Wachholz PA","year":"2002","journal-title":"Th2 cytokine ratios"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2000.00701.x"},{"key":"e_1_2_6_34_2","first-page":"1209","article-title":"Induction of T \u2018regulatory\u2019 cells by standardized house dust mite immunotherapy","volume":"34","author":"Gardner LM","year":"2004","journal-title":"an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2004.01869.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02400.x"},{"key":"e_1_2_6_37_2","first-page":"150","article-title":"Response to sublingual immunotherapy with grass pollen extract","volume":"124","author":"Amar SM","year":"2009","journal-title":"monotherapy versus combination in a multiallergen extract"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.2009.03448.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.2009.03448.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:25:47Z","timestamp":1697394347000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.2009.03448.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2222.2009.03448.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03448.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,6]]}}}